

MHIF Cardiovascular Grand Rounds | March 14, 2022




## GRAND ROUNDS











Palpable dilated superficial vein >3 min diameter
Reticular veins
1-3 mm
Telangectasias (spider veins)
Less than 1 mm
















<image>


































































































Car	moricon	of Toch	igues
CO	liparisor	of Techr	iiques
Mile and The			
	Treated vein	Technique	Adverse Reactions
RFA	GSV, SSV, AASV, IPV	Thermal ablation	EHIT
	Non-tortuous veins	Tumescence	Nerve injury
EVLT	GSV, SSV, AASV, IPV	Thermal ablation	EHIT
	Non-tortuous veins	Tumescence	Nerve injury and skin burns
Cyanoacrylate Glue	GSV, SSV, AASV (<10 mm)	Glue (foreign body)	Phlebitis
	Non- tortuous veins	No tumescence	Hypersensitivity to glue
	Hone tortuous voins		Typersensitivity to glue
		Compression may not be needed	
NOCA	Veins <12 mm	Sclero may diffuse in branches	Sclero related
	Non-tortuous veins	No tumescence	
PEM (1%	Veins < 10mm	Sclero may diffuse into branches	Sclero related
oolidocanol)	Tortuous and partially	No tumescence	Skin discoloration
	thrombosed veins		Thrombophlebitis







	Summa	ry of Pive	otal Studies	5
Technique	Study	Endpoint	Closure Rate	Adverse Events
RFA	Probstle et al	6 months	99.6%	DVT 0% Paresthesia 3-3 2 9
	VeClose (vs glue)	3 months	96%	Phlebitis: 0.8%-3%
EVLT	Min et al	2 years	93.4%	DVT 0%
				Paresthesia 1.1%
Cyanoacrylate glue	VeClose (vs RFA)	3 months	99%	DVT 0% Paresthesia 3% Phlebitis 4%
MOCA	Elias et al	6 months	96.7%	No PE or CVA
PEM (1% polidocanol)	VANISH-1 and 2	8 weeks	80.4-86.2%	DVT 1.9% Phlebitis 7.7%

	Outcome C	comparison (CF	RT)
	Immediate occlusion %	Recanalization at 3 years %	New veins at 3 years %
EVLT	94	7	20
RFA	95	7	15
Foam	80	26	19
Stripping	96	7	20

Immediate failure %DVT/EHIT %Thermal burns %Infection %PhlebitRFA<10<5<1<1<5
<b>RFA</b> <10 <5 <1 <1 <5
<b>EVLT</b> <10 <5 <1 <1 <5
Cyanoacrylate <5 <1 0 <1 <10
MOCA <10 <5 0 <1 <5
PEM <20 <5 0 <1 <20

